Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX)

NCT03255252 is registered in ClinicalTrials.gov with Institut du Cancer de Montpellier - Val d'Aurelle as lead sponsor.

NCT NCT03255252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03255252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX)
Lead sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Phase 2
Overall status
Terminated
Start date
July 15, 2017
Completion date
November 23, 2023
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer